Sharing our perspective

Sharing perspectives leads to greater understanding and fuels innovation. The ​Optum Insights ​blog is where we share our perspective and challenge preconceptions to clear a new path forward.

  • Pennsylvania legislature considering pain treatment guidelines for workers’ compensation claims

    | Jun 15, 2018
    Tag Icon
    Pain Management, Workers' Compensation, formulary, Opioids
    In response to a recent veto of Senate Bill 936 (workers’ comp formulary legislation), the Pennsylvania Legislature has taken up new efforts to establish opioid utilization and treatment controls for workers’ compensation claims.

  • New Jersey Workers’ Comp eBilling rules adopted

    | Jun 13, 2018
    Tag Icon
    eBilling, Workers' Compensation
    The New Jersey Department of Labor and Workforce Development Division of Workers’ Compensation (the department), recently adopted regulations to implement prior electronic medical billing (eBilling) legislation – requiring eBilling effective October 2019. The rules also adopt a 60-day payment timeframe for complete electronic medical bills, which the prior legislation also required.

  • The coming Texas compound preauthorization requirement: Attention to grandfathered prescriptions

    • Optum for Workers' Compensation
    | Jun 12, 2018
    Tag Icon
    Workers' Compensation, Compounded Medications
    The Texas Division of Workers’ Compensation adopted changes to its Closed Formulary to require preauthorization for all compounded medications, regardless of ingredient makeup. The new preauthorization requirement takes effect for prescriptions written and dispensed on or after July 1, 2018.

  • Drug Recall: Two lots of Naloxone injection recalled

    • Optum Workers' Comp
    | Jun 06, 2018
    Tag Icon
    Workers' Compensation, Naloxone, FDA
    The U.S. Food and Drug Administration (FDA) announced that Hospira, Inc., a Pfizer company, voluntarily recalled two lots of naloxone hydrochloride injection at the hospital and institution level. Naloxone injection is used in the emergency treatment of a known or suspected opioid overdose. However, this recall does not affect the naloxone products Evzio® auto-injector or Narcan® Nasal Spray.